Ionis Pharmaceuticals Competitors
| IONS Stock | USD 75.71 -0.31 -0.41% |
Correlation: Ionis Pharmaceuticals vs Guardant Health Summary
Very poor diversification
Across the chosen horizon, Ionis Pharmaceuticals and Guardant Health show a correlation of 0.83 and fall into the Very poor diversification bucket. A 0.83 reading means Ionis Pharmaceuticals and Guardant Health have substantial price overlap, limiting risk reduction through pairing.
Experienced market participants anticipate that Ionis Pharmaceuticals' price will even out over time. Periods when Ionis Pharmaceuticals' deviates significantly from its historical mean may warrant further fundamental analysis. Mean reversion in Ionis Pharmaceuticals' serves as a complement to momentum analysis.
Ionis Pharmaceuticals Competition Correlation Matrix
Correlation analysis between Ionis Pharmaceuticals and its competitors provides context for understanding whether diversification is real or only superficial inside the same peer group. This matrix is most informative when seeking to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
Please upgrade your account to get full access to Macroaxis premium features
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Strong recent returns in Ionis Stock do not always mean Ionis Pharmaceuticals Company is outperforming peers on business quality. Reviewing Ionis Pharmaceuticals' risk-adjusted indicators gives a clearer view of whether returns are being earned efficiently. These indicators are quantitative in nature and measure volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ASND | 1.90 | 0.15 | 0.07 | 0.20 | 1.96 | 4.42 | 9.84 | |||
| BBIO | 2.35 | -0.18 | 0.00 | -0.12 | 0.00 | 6.23 | 19.68 | |||
| RVMD | 2.71 | 0.72 | 0.31 | 0.65 | 1.86 | 6.04 | 46.32 | |||
| ROIV | 2.02 | 0.42 | 0.22 | 0.23 | 1.68 | 4.88 | 25.93 | |||
| SMMT | 3.41 | 0.38 | 0.06 | 0.21 | 5.45 | 8.23 | 40.56 | |||
| BMRN | 1.36 | -0.09 | 0.00 | -0.15 | 0.00 | 3.10 | 7.25 | |||
| EXEL | 1.57 | 0.13 | 0.06 | 0.15 | 1.98 | 2.93 | 10.49 | |||
| MDGL | 1.87 | 0.18 | 0.07 | 0.27 | 2.49 | 3.80 | 16.42 | |||
| MRNA | 2.70 | 0.26 | 0.08 | 0.18 | 2.94 | 6.08 | 23.48 | |||
| GH | 2.63 | -0.27 | 0.00 | -0.16 | 0.00 | 4.59 | 16.99 |
Peer Comparison: Net Income
Net income is what remains after all costs — operating expenses, interest, taxes, and preferred dividends — are deducted from Ionis Pharmaceuticals's total revenue. The relationship between net income growth and revenue growth at Ionis Pharmaceuticals reveals whether margin expansion is driving earnings or whether top-line growth is being consumed by rising costs and financing charges.Compare Ionis Pharmaceuticals and related stocks such as Ascendis Pharma AS, BridgeBio Pharma, and Revolution Medicines Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | -9.7 M | -32.9 M | -68.5 M | -123.9 M | -130.1 M | -218 M | -419 M | -383.6 M | -583.2 M | -481.4 M | -378.1 M | -219 M | -230 M |
| BBIO | -30.6 M | -30.6 M | -30.6 M | -30.6 M | -30.6 M | -30.6 M | -30.6 M | -30.6 M | -130.7 M | -260.4 M | -448.7 M | -562.5 M | -481.2 M | -643.2 M | -535.8 M | -729.3 M | -692.8 M |
| RVMD | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -41.8 M | -47.7 M | -108.2 M | -187.1 M | -248.7 M | -436.4 M | -600.1 M | -1.1 B | -1.1 B |
| ROIV | -1 B | -1 B | -1 B | -1 B | -1 B | -1 B | -1 B | -1 B | -1 B | 1.2 B | -809.2 M | -845.3 M | -1 B | 4.3 B | -172 M | -197.8 M | -187.9 M |
| SMMT | -42 K | -4.2 M | -6.7 M | -6.1 M | -17.1 M | -24.3 M | -22.7 M | -28.5 M | 10.9 M | 5 M | -52.7 M | -86.1 M | -65.2 M | -482.4 M | -176.8 M | -1.1 B | -1 B |
| BMRN | -12.3 M | -53.8 M | -114.3 M | -176.4 M | -134 M | -171.8 M | -630.2 M | -117 M | -77.2 M | -23.8 M | 854 M | -64.1 M | 141.6 M | 167.6 M | 426.9 M | 348.9 M | 366.3 M |
| EXEL | -15.7 M | 75.7 M | -147.6 M | -244.8 M | -268.5 M | -169.7 M | -70.2 M | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 782.6 M | 821.7 M |
| MDGL | -381 K | -47.4 M | -62.8 M | -90.2 M | -86.2 M | -6.8 M | -26.4 M | -31.2 M | -32.8 M | -72.8 M | -197.4 M | -241.1 M | -295.4 M | -373.6 M | -465.9 M | -288.3 M | -273.9 M |
| MRNA | -6.5 M | -6.5 M | -6.5 M | -6.5 M | -6.5 M | -1.1 M | -216.2 M | -255.9 M | -384.7 M | -514 M | -747.1 M | 12.2 B | 8.4 B | -4.7 B | -3.6 B | -2.8 B | -2.7 B |
| GH | -46.1 M | -46.1 M | -46.1 M | -46.1 M | -46.1 M | -46.1 M | -46.1 M | -83.2 M | -85.1 M | -75.7 M | -253.8 M | -405.7 M | -654.6 M | -479.4 M | -436.4 M | -416.3 M | -437.1 M |
Ionis Pharmaceuticals Competitive Analysis
Within its peer group that includes Ascendis Pharma, BridgeBio Pharma, and Revolution Medicines, Ionis Pharmaceuticals stands out in several ways. The company commands a 12.70 B market valuation built on 944.0 M in annual revenue. The -67.62% return on equity and -30.90% profit margin point to near-term profitability challenges for Ionis Pharmaceuticals. Return on equity favors Ionis Pharmaceuticals at -67.62%, well ahead of Ascendis Pharma at -818.43%. Profit margins tilt toward Ionis Pharmaceuticals at -30.90% against BridgeBio Pharma at -144.39%. Market capitalization diverges sharply here: 32.12 B versus 12.70 B, giving Revolution Medicines a clear size advantage.| Better Than Average | Worse Than Peers | View Performance Chart |
Ionis Pharmaceuticals Competition Peer Performance Charts
How to Analyze Ionis Pharmaceuticals Against Peers
Ionis Pharmaceuticals' peer analysis compares Ionis Pharmaceuticals with related companies to put valuation, quality, and risk metrics in context. This establishes whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Ionis Pharmaceuticals trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Ionis Pharmaceuticals leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Ionis Pharmaceuticals has a wider economic moat score than the average competitor, based on return spread and reinvestment patterns. A cheap stock in an expensive peer group sometimes signals a value trap rather than an opportunity. Peer comparisons can reduce single-name bias by forcing a wider operating and valuation context. For peer comparison, Ionis Pharmaceuticals has a market cap of 12.7 billion, P/E of 101.16, profit margin of -30.9%.
Ionis Pharmaceuticals analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Where analyst coverage exists, consensus estimates are factored in.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board